Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §2

Tobacco and nicotine dependence — evidence across compounds

Every compound the Institute assesses in tobacco and nicotine dependence, with its certainty rating.

Document identifier
CEI-IN-14/2
Series
Indication assessment
Version
2.1
Published
09 Jan 2024
Last reviewed
09 Jan 2024
Next review
09 Jan 2026
Identifier
10.71829/cei.ind.14
Certainty
Not rated
Cycle
2024 Q1
ICD-11
6C4A
Category
Neuropsychiatric

§2Evidence across compounds

Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.

No compound in the Institute's set has an assessed outcome in this indication.

§2.1Syntheses bearing on this indication

No evidence synthesis addresses this indication.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.